1.09
price down icon0.91%   -0.01
after-market アフターアワーズ: 1.07 -0.02 -1.83%
loading
前日終値:
$1.10
開ける:
$1.06
24時間の取引高:
967.05K
Relative Volume:
0.86
時価総額:
$85.30M
収益:
$101.21M
当期純損益:
$-569.00K
株価収益率:
-1.2976
EPS:
-0.84
ネットキャッシュフロー:
$-56.88M
1週間 パフォーマンス:
-1.80%
1か月 パフォーマンス:
+25.27%
6か月 パフォーマンス:
-14.84%
1年 パフォーマンス:
-18.66%
1日の値動き範囲:
Value
$1.03
$1.10
1週間の範囲:
Value
$1.00
$1.16
52週間の値動き範囲:
Value
$0.833
$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
名前
Cytomx Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
650.515.3185
Name
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
職員
122
Name
Twitter
@cytomxinc
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
CTMX's Discussions on Twitter

CTMX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CTMX
Cytomx Therapeutics Inc
1.09 85.30M 101.21M -569.00K -56.88M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-05-28 アップグレード Piper Sandler Neutral → Overweight
2024-05-09 アップグレード Wedbush Neutral → Outperform
2024-05-06 アップグレード Jefferies Hold → Buy
2024-04-22 アップグレード JP Morgan Underweight → Neutral
2022-11-14 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-07-07 ダウングレード Jefferies Buy → Hold
2022-07-07 ダウングレード Mizuho Buy → Neutral
2022-07-07 ダウングレード Piper Sandler Overweight → Neutral
2022-07-07 ダウングレード Wedbush Outperform → Neutral
2022-06-24 開始されました BMO Capital Markets Outperform
2022-01-18 アップグレード Barclays Underweight → Overweight
2021-11-15 開始されました BTIG Research Buy
2021-05-28 ダウングレード Barclays Equal Weight → Underweight
2021-03-29 開始されました JP Morgan Overweight
2021-03-23 アップグレード Jefferies Hold → Buy
2020-09-22 ダウングレード Guggenheim Buy → Neutral
2020-06-01 ダウングレード Jefferies Buy → Hold
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-03-24 アップグレード Wedbush Neutral → Outperform
2020-03-04 開始されました Barclays Equal Weight
2019-11-20 開始されました Guggenheim Buy
2019-11-11 ダウングレード Wedbush Outperform → Neutral
2019-06-13 開始されました Mizuho Buy
2019-05-14 開始されました Cantor Fitzgerald Overweight
2019-03-11 開始されました Barclays Overweight
2018-11-26 開始されました Piper Jaffray Overweight
2018-10-15 開始されました Goldman Neutral
2018-09-13 開始されました H.C. Wainwright Buy
2018-06-01 開始されました SunTrust Buy
2018-01-05 開始されました Citigroup Buy
2017-09-08 開始されました Wedbush Outperform
2017-03-27 開始されました H.C. Wainwright Buy
2017-03-02 開始されました Instinet Buy
2017-01-03 ダウングレード Oppenheimer Outperform → Perform
2015-11-02 開始されました Oppenheimer Outperform
すべてを表示

Cytomx Therapeutics Inc (CTMX) 最新ニュース

pulisher
03:13 AM

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Position Raised by Fmr LLC - Defense World

03:13 AM
pulisher
Dec 20, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 20, 2024
pulisher
Dec 18, 2024

CytomX Therapeutics (NASDAQ:CTMX) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS - MSN

Dec 18, 2024
pulisher
Dec 17, 2024

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry - Simply Wall St

Dec 17, 2024
pulisher
Dec 16, 2024

CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Dec 16, 2024
pulisher
Dec 13, 2024

CytomX Therapeutics' SWOT analysis: biotech stock's solid tumor focus By Investing.com - Investing.com Canada

Dec 13, 2024
pulisher
Dec 10, 2024

Janus Henderson Group PLC Trims Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - MarketBeat

Dec 10, 2024
pulisher
Dec 06, 2024

Recent uptick might appease CytomX Therapeutics, Inc. (NASDAQ:CTMX) institutional owners after losing 21% over the past year - Simply Wall St

Dec 06, 2024
pulisher
Nov 30, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 21.7% in November - MarketBeat

Nov 30, 2024
pulisher
Nov 28, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Brokerages - Defense World

Nov 28, 2024
pulisher
Nov 27, 2024

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - The Manila Times

Nov 27, 2024
pulisher
Nov 25, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Analysts - MarketBeat

Nov 25, 2024
pulisher
Nov 19, 2024

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround - Yahoo Finance

Nov 19, 2024
pulisher
Nov 15, 2024

CytomX stock touches 52-week low at $0.98 amid market challenges - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

Biotechnology Value Fund L P Increases Stake in CytomX Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

TANG CAPITAL MANAGEMENT LLC Acquires Shares in CytomX Therapeuti - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Cy - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

HC Wainwright Has Bullish Estimate for CTMX FY2024 Earnings - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

HC Wainwright Has Positive Outlook for CTMX FY2024 Earnings - MarketBeat

Nov 13, 2024
pulisher
Nov 12, 2024

CytomX Therapeutics' SWOT analysis: biotech stock's potential in cancer treatment - Investing.com UK

Nov 12, 2024
pulisher
Nov 11, 2024

CytomX Therapeutics (NASDAQ:CTMX) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024
pulisher
Nov 09, 2024

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Inc earnings beat by $0.24, revenue topped estimates - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates - MSN

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics: Q3 Earnings Snapshot - Darien Times

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Reports Q3 Progress and Growth - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

CytomX stock touches 52-week low at $0.98 amid market shifts - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 07, 2024
pulisher
Nov 06, 2024

Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 202 - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result - Yahoo Finance

Nov 06, 2024
pulisher
Nov 03, 2024

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - MarketBeat

Oct 31, 2024
pulisher
Oct 26, 2024

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues - Simply Wall St

Oct 26, 2024
pulisher
Oct 25, 2024

CytomX stock plunges to 52-week low at $1.03 amid market challenges - Investing.com India

Oct 25, 2024
pulisher
Oct 23, 2024

CytomX Therapeutics, Inc.($CTMX) - substack.com

Oct 23, 2024
pulisher
Oct 17, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in September - MarketBeat

Oct 17, 2024
pulisher
Oct 15, 2024

CytomX Therapeutics Inc (CTMX) rating upgrades by Piper Sandler - Knox Daily

Oct 15, 2024

Cytomx Therapeutics Inc (CTMX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Cytomx Therapeutics Inc (CTMX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Landau Jeffrey B
Chief Business Officer
Aug 20 '24
Sale
1.23
4,181
5,139
119,056
BELVIN MARCIA
SVP, Chief Scientific Officer
Aug 20 '24
Option Exercise
0.00
11,250
0
179,829
BELVIN MARCIA
SVP, Chief Scientific Officer
Aug 20 '24
Sale
1.23
4,181
5,139
175,648
ROWLAND LLOYD A
General Counsel
Aug 20 '24
Option Exercise
0.00
11,250
0
134,978
ROWLAND LLOYD A
General Counsel
Aug 20 '24
Sale
1.23
4,181
5,139
130,797
Ogden Christopher
Chief Financial Officer
Aug 20 '24
Option Exercise
0.00
6,875
0
110,061
Ogden Christopher
Chief Financial Officer
Aug 20 '24
Sale
1.23
1,984
2,439
108,077
McCarthy Sean A.
CEO
Aug 20 '24
Option Exercise
0.00
37,500
0
671,749
McCarthy Sean A.
CEO
Aug 20 '24
Sale
1.23
13,898
17,082
657,851
McCarthy Sean A.
CEO
Mar 26 '24
Option Exercise
1.57
109,768
172,874
634,249
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
大文字化:     |  ボリューム (24 時間):